FibroGen (NASDAQ:FGEN) Now Covered by StockNews.com

Stock analysts at StockNews.com began coverage on shares of FibroGen (NASDAQ:FGEN) in a report released on Friday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Separately, William Blair restated a “market perform” rating on shares of FibroGen in a research report on Wednesday, November 13th.

FibroGen Trading Up 10.6 %

Shares of FGEN opened at $0.39 on Friday. The business’s 50-day moving average price is $0.36 and its 200 day moving average price is $0.69. The stock has a market capitalization of $39.02 million, a P/E ratio of -0.31 and a beta of 0.72. FibroGen has a 1-year low of $0.18 and a 1-year high of $2.93.

FibroGen (NASDAQ:FGEN) last issued its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.21. The company had revenue of $46.33 million during the quarter, compared to analysts’ expectations of $34.00 million. During the same period in the prior year, the business posted ($0.52) EPS. On average, research analysts predict that FibroGen will post -0.86 earnings per share for the current year.

Institutional Investors Weigh In On FibroGen

Institutional investors have recently bought and sold shares of the business. Cubist Systematic Strategies LLC boosted its position in FibroGen by 3,906.9% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 287,332 shares of the biopharmaceutical company’s stock worth $256,000 after acquiring an additional 280,161 shares during the period. Point72 DIFC Ltd lifted its holdings in shares of FibroGen by 734.2% during the 2nd quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 45,990 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of FibroGen during the 2nd quarter valued at about $424,000. Acadian Asset Management LLC lifted its holdings in shares of FibroGen by 34.4% during the 2nd quarter. Acadian Asset Management LLC now owns 3,364,719 shares of the biopharmaceutical company’s stock valued at $2,997,000 after buying an additional 860,854 shares during the last quarter. Finally, Sei Investments Co. lifted its holdings in shares of FibroGen by 38.4% during the 2nd quarter. Sei Investments Co. now owns 149,342 shares of the biopharmaceutical company’s stock valued at $133,000 after buying an additional 41,442 shares during the last quarter. 72.71% of the stock is currently owned by institutional investors and hedge funds.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.